What type of study is this?

This is a In Vitro Study study.

What question did this study set out to answer?

To develop a scalable in vivo CAR-T therapy using novel T-cell-targeted lipid nanoparticles encapsulating mRNA.

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Preclinical evaluation reveals in vivo CAR-T therapy achieves over 95% B cell depletion, suggesting improved anti-tumor efficacy.

To develop a scalable in vivo CAR-T therapy using novel T-cell-targeted lipid nanoparticles encapsulating mRNA.
Developed GT801 with T-LNP encapsulating anti-CD19 CAR mRNA.
Optimized LNP formulation and mRNA design for targeted delivery and CAR functionality.
Evaluated efficacy and pharmacodynamics in humanized NOG mouse models.
Achieved over 95% B cell depletion with a single intravenous dose of 0.01 mg/kg.
Sustained CAR expression in human PBMC for over 14 days in vitro.
Demonstrated potent anti-tumor activity in cell line-derived xenograft models.

Sun et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark